Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the ...

Curi Bio’s ribbon cutting in April 2025 for its new headquarters on Seattle’s waterfront. Elliot Fisher, co-founder and chief business officer, cuts the ribbon with a sword while CEO Nicholas Geisse ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) ranks among the best medical stocks to buy according to analysts. On July 31, Bio-Rad Laboratories, Inc. (NYSE:BIO) posted second-quarter earnings that far ...